Cargando…

Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome

The Ts65Dn mouse is the most studied animal model of Down syndrome. Past research has shown a significant reduction in CA1 hippocampal long-term potentiation (LTP) induced by theta-burst stimulation (TBS), but not in LTP induced by high-frequency stimulation (HFS), in slices from Ts65Dn mice compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott-McKean, Jonah J., Roque, Adriano L., Surewicz, Krystyna, Johnson, Mark W., Surewicz, Witold K., Costa, Alberto C. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914153/
https://www.ncbi.nlm.nih.gov/pubmed/29849573
http://dx.doi.org/10.1155/2018/9235796
_version_ 1783316661373239296
author Scott-McKean, Jonah J.
Roque, Adriano L.
Surewicz, Krystyna
Johnson, Mark W.
Surewicz, Witold K.
Costa, Alberto C. S.
author_facet Scott-McKean, Jonah J.
Roque, Adriano L.
Surewicz, Krystyna
Johnson, Mark W.
Surewicz, Witold K.
Costa, Alberto C. S.
author_sort Scott-McKean, Jonah J.
collection PubMed
description The Ts65Dn mouse is the most studied animal model of Down syndrome. Past research has shown a significant reduction in CA1 hippocampal long-term potentiation (LTP) induced by theta-burst stimulation (TBS), but not in LTP induced by high-frequency stimulation (HFS), in slices from Ts65Dn mice compared with euploid mouse-derived slices. Additionally, therapeutically relevant doses of the drug memantine were shown to rescue learning and memory deficits in Ts65Dn mice. Here, we observed that 1 μM memantine had no detectable effect on HFS-induced LTP in either Ts65Dn- or control-derived slices, but it rescued TBS-induced LTP in Ts65Dn-derived slices to control euploid levels. Then, we assessed LTP induced by four HFS (4xHFS) and found that this form of LTP was significantly depressed in Ts65Dn slices when compared with LTP in euploid control slices. Memantine, however, did not rescue this phenotype. Because 4xHFS-induced LTP had not yet been characterized in Ts65Dn mice, we also investigated the effects of picrotoxin, amyloid beta oligomers, and soluble recombinant human prion protein (rPrP) on this form of LTP. Whereas ≥10 μM picrotoxin increased LTP to control levels, it also caused seizure-like oscillations. Neither amyloid beta oligomers nor rPrP had any effect on 4xHFS-induced LTP in Ts65Dn-derived slices.
format Online
Article
Text
id pubmed-5914153
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59141532018-05-30 Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome Scott-McKean, Jonah J. Roque, Adriano L. Surewicz, Krystyna Johnson, Mark W. Surewicz, Witold K. Costa, Alberto C. S. Neural Plast Research Article The Ts65Dn mouse is the most studied animal model of Down syndrome. Past research has shown a significant reduction in CA1 hippocampal long-term potentiation (LTP) induced by theta-burst stimulation (TBS), but not in LTP induced by high-frequency stimulation (HFS), in slices from Ts65Dn mice compared with euploid mouse-derived slices. Additionally, therapeutically relevant doses of the drug memantine were shown to rescue learning and memory deficits in Ts65Dn mice. Here, we observed that 1 μM memantine had no detectable effect on HFS-induced LTP in either Ts65Dn- or control-derived slices, but it rescued TBS-induced LTP in Ts65Dn-derived slices to control euploid levels. Then, we assessed LTP induced by four HFS (4xHFS) and found that this form of LTP was significantly depressed in Ts65Dn slices when compared with LTP in euploid control slices. Memantine, however, did not rescue this phenotype. Because 4xHFS-induced LTP had not yet been characterized in Ts65Dn mice, we also investigated the effects of picrotoxin, amyloid beta oligomers, and soluble recombinant human prion protein (rPrP) on this form of LTP. Whereas ≥10 μM picrotoxin increased LTP to control levels, it also caused seizure-like oscillations. Neither amyloid beta oligomers nor rPrP had any effect on 4xHFS-induced LTP in Ts65Dn-derived slices. Hindawi 2018-04-10 /pmc/articles/PMC5914153/ /pubmed/29849573 http://dx.doi.org/10.1155/2018/9235796 Text en Copyright © 2018 Jonah J. Scott-McKean et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Scott-McKean, Jonah J.
Roque, Adriano L.
Surewicz, Krystyna
Johnson, Mark W.
Surewicz, Witold K.
Costa, Alberto C. S.
Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
title Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
title_full Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
title_fullStr Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
title_full_unstemmed Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
title_short Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
title_sort pharmacological modulation of three modalities of ca1 hippocampal long-term potentiation in the ts65dn mouse model of down syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914153/
https://www.ncbi.nlm.nih.gov/pubmed/29849573
http://dx.doi.org/10.1155/2018/9235796
work_keys_str_mv AT scottmckeanjonahj pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome
AT roqueadrianol pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome
AT surewiczkrystyna pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome
AT johnsonmarkw pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome
AT surewiczwitoldk pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome
AT costaalbertocs pharmacologicalmodulationofthreemodalitiesofca1hippocampallongtermpotentiationinthets65dnmousemodelofdownsyndrome